Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01491620
Other study ID # C-11-XPC01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2011
Est. completion date May 2013

Study information

Verified date October 2022
Source Cutera Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of the Excel V 532 nm KTP laser for the treatment of dyschromia of the neck and/or chest (poikiloderma of Civatte).


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date May 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender All
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria: - Fitzpatrick Skin Type I - III - Clinical diagnosis of poikiloderma of Civatte affecting the neck and/or chest - Willing to refrain from using topical corticosteroids, retinoids and bleaching agents on the treated area - Agree not to undergo any other procedure for the treatment of poikiloderma of Civatte during the study - Willing and able to read, understand and sign the Informed Consent Form - Willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions Exclusion Criteria: - Any laser treatment on neck and/or chest within 12 months - Any topical treatment on neck and/or chest within 6 months - Pregnant and/or breastfeeding - Infection, dermatitis or a rash in the treatment area - Suffering from significant concurrent illness, such as Diabetes Mellitus or pertinent neurological disorders - History of seizure disorders due to light, fibromyalgia, connective tissue disease, vitiligo, psoriasis, pigmentary disorders, keloid scarring, hypertrophic scarring or abnormal wound healing - History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications - Having a known anticoagulative condition or taking anticoagulation medications - History of diseases stimulated by heat, unless treatment is conducted following a prophylactic regimen - Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely) - History of radiation to the head, neck and/or upper chest - Undergoing systemic chemotherapy for the treatment of cancer - Systemic use of isotretinoin (Accutane®) within 6 months - Any use of gold therapy - Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study - Current smoker or history of smoking within 12 months of study - Participation in a study of another device or drug within 6 months - As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in study

Study Design


Intervention

Device:
532 nm KTP laser
Laser treatment sessions on the neck and/or chest

Locations

Country Name City State
United States Zel Skin and Laser Specialists Edina Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Cutera Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severity Assessment Score Change in Physician's Severity Assessment score based on blinded assessment of subject photographs by a panel of independent dermatologists.
Blinded Physician's Severity Assessment (min=1;max=4); Higher scores mean worse values
24 weeks
Primary Physician's Global Assessment (Blinded) Before and after subject photographs were presented to a panel of independent dermatologists. The panel was blinded to treatment parameters and the photograph time points. Each dermatologist was asked to select the baseline photograph and then rate improvement in Poikiloderma of Civatte in the post-treatment photograph using a 5-point improvement scale.
Physician's Global Assessment (min= -1; max=4) Higher scores mean better outcome
24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Completed NCT00378196 - Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial Phase 1
Terminated NCT04336163 - Skin Imaging to Inform Laser Treatments N/A
Completed NCT02286804 - Ultherapy for the Treatment of Spider Veins on the Legs N/A
Completed NCT03472859 - Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser N/A
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Completed NCT04148950 - Effects of Kinesio Taping Method on Functional Capacity and Quality of Life in Patients With Chronic Venous Disease N/A
Completed NCT00457145 - Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation Phase 1
Completed NCT00457067 - Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation Phase 1
Completed NCT04795310 - Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia N/A
Completed NCT04274842 - D-OCT of Facial Telangiectasia Treated With IPL N/A
Recruiting NCT05978986 - Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence N/A
Completed NCT05036200 - Pilot Study to Evaluate the Interest of PDL in the Management of Telangiectasia of the Face and Neckline in Systemic Scleroderma N/A